

**Active Biotech AB  
Interim report  
January – June 2009**

- **Laquinimod — BRAVO Phase III trial fully enrolled**
- **57-57 — explorative clinical trial initiated**
- **RhuDex<sup>™</sup> — preclinical tests in progress**
- **ANYARA — Phase III trial fully enrolled**
- **TASQ — Phase II trial fully enrolled**
- **ISI – target molecule for Q compounds published**
- **Net sales of SEK 5.2 M (5.8)**
- **Operating loss of SEK 118.5 M (loss: 104.7)**
- **Loss after tax of SEK 118.6 M (loss: 99.3)**
- **Loss per share for the period of SEK 2.22 (loss 2.07)**
- **Implemented rights issue contributed approximately SEK 249 M**
- **Number of shares at the end of the period (incl. warrants), 65,052,238**

**For further information, please contact:**

Tomas Leanderson  
President and CEO  
Tel: +46 (0)46-19 20 95

Göran Forsberg  
VP Investor Relations & Business Development  
Tel: +46 (0)46-19 11 54

Hans Kolam  
CFO  
Tel: +46 (0)46-19 20 44

Active Biotech AB  
(Corp. Reg. No. 556223-9227)  
PO Box 724, SE-220 07 Lund  
Sweden  
Tel: +46 (0)46-19 20 00  
Fax: +46 (0)46-19 11 00

This report is also available at [www.activebiotech.com](http://www.activebiotech.com)

## **Laquinimod – a novel oral immunomodulatory compound for the treatment of autoimmune diseases**

*Laquinimod is a quinoline compound in Phase III development for the treatment of [multiple sclerosis \(MS\)](#). Active Biotech has entered into an agreement with the Israeli pharmaceutical company [Teva Pharmaceutical Industries Ltd](#) (June 2004) covering the development and commercialization of laquinimod. Positive data from a [Phase IIb trial](#) of relapsing-remitting multiple sclerosis (RRMS) has been published in the scientific journal *The Lancet* (2008; 371:2085-92). In September 2008, data from the post-Phase IIb [extension study](#) showed a significant decrease in the mean number of gadolinium-enhancing (GdE) lesions in the brains of both the patients who had switched from placebo to laquinimod and the patients who had continued with their initial laquinimod dose. At present, laquinimod is undergoing two global clinical Phase III trials, which will encompass a total of 2,200 MS patients in 175 clinics worldwide. In November 2008, Teva completed patent enrolment for the first of two Phase III studies ([Allegro](#)). In February 2009, laquinimod received a “Fast track” designation from the US Food and Drug Administration, FDA. Information regarding the ongoing clinical trials is available at [www.TevaClinicalTrials.com](http://www.TevaClinicalTrials.com) and [www.clinicaltrials.gov](http://www.clinicaltrials.gov).*

– In June, it was announced that laquinimod’s second pivotal clinical Phase III trial for the treatment of RRMS, BRAVO, had been fully enrolled following the inclusion of more than 1,200 patients. BRAVO is a global clinical trial aimed at evaluating the efficiency, safety and tolerability of laquinimod compared with placebo, and will also provide risk-benefit data for laquinimod, compared with an injected RRMS product currently available on the market, Avonex®.

The BRAVO trial is being conducted in 156 different clinics in the US, Europe, Israel and South Africa.

## **57-57 – a novel oral immunomodulatory compound for the treatment of Systemic Lupus Erythematosus**

*57-57 is a quinoline compound primarily intended for the treatment of [Systemic Lupus Erythematosus \(SLE\)](#), a disease that causes inflammation and damage to connective tissue throughout the body, with serious secondary symptoms, such as kidney failure. Earlier documentation from [preclinical trials](#) indicates that 57-57 can prevent relapses and reduce steroid use in SLE patients. At the American College of Rheumatology’s Annual Scientific Meeting in October 2008, new data from the [Phase I trial](#) of 57-57 were presented.*

– Updated data from the concluded clinical Phase Ib trial for 57-57 was presented in June at the 10<sup>th</sup> Annual Congress of the European League against Rheumatism (EULAR) – an international meeting of rheumatology specialists. The general safety profile throughout the entire trial was excellent. The new results strengthen previous data indicating that treatment with 57-57 could influence signal routes that are significant in the development of SLE. View the complete poster “A Phase I, Dose-Escalation Study to Evaluate the Tolerability of ABR-215757 in patients with Systemic Lupus Erythematosus (SLE)” [here](#).

A small-scale explorative clinical study in SLE patients has been initiated. This study will include approximately 15 patients who are treated with 3 mg of 57-57 daily. Several parameters that correlate with the disease activity will be studied in detail. The study is expected to be concluded during 2010.

## **RhuDex™ – a novel oral compound for the treatment of rheumatoid arthritis**

*In the project covering Active Biotech’s patented CD80 antagonists, the RhuDex candidate drug is under development for the treatment of [rheumatoid arthritis \(RA\)](#). In April 2002, Active Biotech entered a licensing agreement with Avidex Ltd, now a wholly owned subsidiary of the German biotechnology company [MediGene](#), according to which MediGene has the exclusive rights to develop CD80 antagonists and market products in which these compounds are included. Two [Phase I trials](#) have already been successfully implemented in which the RhuDex candidate drug’s safety, tolerability and pharmacokinetic properties in healthy volunteers were studied. In June 2008, MediGene announced that a clinical [Phase IIa trial](#) had achieved its objective. For further information and the latest news concerning RhuDex, visit [www.medigene.com](http://www.medigene.com).*

– RhuDex™ is currently being [studied](#) in a series of laboratory tests under the supervision of the UK Medicines and Healthcare Products Regulatory Agency. These tests will examine any potential detrimental interactions between RhuDex and arteriosclerotic blood vessels. MediGene plans to complete these tests in mid-2009 and subsequently initiate Phase IIb clinical trials.

#### **ANYARA – a fusion protein for immunological treatment of renal cancer**

*ANYARA is a [TTS](#) (Tumor Targeting Superantigens) compound that makes the treatment of cancer tumor-specific. The development of ANYARA is mainly focused on [renal cell cancer](#). Positive data was reported in connection with the [interim analysis in Phase II/III](#) and from clinical Phase I trials in lung cancer, renal cell cancer and pancreatic cancer. The median survival of 26.2 months observed for patients with advanced renal cell cancer and treated with ANYARA is twice the expected length. Pivotal [Phase III trials](#) in patients with advanced renal cell cancer are currently under way. The primary clinical efficacy parameter from this trial is overall survival and it will include a total of approximately 500 patients at about 50 clinics in Europe. ANYARA has been granted [orphan-drug status](#) by the EMEA for the indication renal cell cancer. Information concerning the ongoing clinical trial is available at [www.activebiotech.com](http://www.activebiotech.com) and [www.clinicaltrials.gov](http://www.clinicaltrials.gov).*

– Patient enrolment to the pivotal clinical Phase III study for ANYARA was completed in June following the enrolment of more than 500 patients. This Phase III study will evaluate the effect of ANYARA in combination with interferon-alpha, compared with interferon-alpha alone, in patients with advanced renal cell cancer. The primary clinical efficacy parameter from this trial is overall survival and the current assessment is that the results will be presented at the end of 2010/beginning of 2011.

#### **TASQ – an antiangiogenic compound for the treatment of prostate cancer**

*The development of TASQ is principally focused on the treatment of [prostate cancer](#). TASQ is an antiangiogenic compound, meaning that it cuts off the supply of nutrients to the tumor but it does not belong to the most frequently occurring group of tyrosine kinase inhibitors. Positive results for the concluded [Phase I trial](#) show that TASQ is well-tolerated and has a favorable safety profile. In September 2008, the follow-up efficacy data from the Phase Ib trial of TASQ was presented, which showed that patients treated with TASQ developed few new bone metastases and displayed a reduced rate of increase of the disease marker PSA (Prostate-Specific Antigen). The project is currently in a placebo-controlled clinical Phase II trial in progress in the US, Canada and Sweden. Information about the ongoing clinical trial is available at [www.activebiotech.com](http://www.activebiotech.com) and [www.clinicaltrials.gov](http://www.clinicaltrials.gov).*

– Patient enrolment for the ongoing clinical Phase II study of TASQ was completed in June following the enrolment of 200 patients. The trial is a 2:1 random, placebo-controlled, double-blind study of 1mg/day TASQ, compared with placebo. The study includes symptom-free patients with metastasized, hormone-resistant prostate cancer.

The primary objective of the study is to measure the proportion of disease progression among the patients after six months of treatment with TASQ, compared with placebo. The results from this study are expected in late 2009/early 2010.

#### **ISI (Inhibition of S100 interactions) – new project based on the mode of action of quinoline compounds**

*Active Biotech is conducting a new research project aimed at utilizing the company's own preclinical results that were generated around a target molecule for the quinoline (Q) compounds and their biological mode of action. The project aims at producing new, patentable chemical substances that interact with the target molecule of the Q compounds. The aim is to select a candidate drug during 2010.*

– In April, the [results](#) on a target molecule for the quinoline (Q) compounds were published in PLoS Biology (Volume 7, Issue 4, pages 800-812). The study showed that Q compounds bind to a molecule called S100A9, which is expressed in white blood cells involved in the regulation of immune responses. Furthermore, it was shown that S100A9 interacts with two known pro-inflammatory receptors (Toll like receptor 4 (TLR4) and receptor of advanced glycation end products (RAGE)) and that this interaction is inhibited by Q compounds.

## **Events after the end of the period**

### [ANYARA Phase I data presented in Journal of Clinical Oncology](#)

The Journal of Clinical Oncology, a scientific publication, published an article in which Active Biotech's cancer project, ANYARA, was studied both as a monotherapy and in combination with an established cancer drug – docetaxel (Taxotere®) – in patients with advanced cancer. The results showed that ANYARA was tolerated well. ANYARA displayed immunologic activity and results concerning the anti-tumor activity were presented.

## **Financial information**

### **Comments on the Group's results for the period January – June 2009**

Net sales for the period amounted to SEK 5.2 M (5.8) and derived from service and rental revenues. The figure for the year-earlier period also included research grants of SEK 1.7 M from Vinnova.

The operation's research and administration expenses totaled SEK 123.7 M (110.6), of which research costs accounted for SEK 114.1 M (98.4). The increase in costs was mainly due to the ongoing Phase III trial for the ANYARA renal cancer project, the ongoing Phase II trial for the TASQ prostate cancer project and the 57-57 project for the treatment of SLE. In addition, Active Biotech conducted studies to explain the mode of action and target molecules underlying the pharmacological effects of the quinoline compounds currently in clinical development. Costs for the period were negatively impacted by the weakening of the Swedish krona, since approximately 45% of research costs consist of research services that are primarily invoiced in foreign currency.

The clinical development of RhuDex™ for the treatment of RA and the ongoing clinical Phase III studies with laquinimod are fully financed by the relevant partners.

An operating loss of SEK 118.5 M (loss: 104.7) was reported. The change was attributable to higher costs for the more comprehensive clinical development program. Net financial expense for the period totaled SEK 0.1 M (income: 5.4), with net financial income for the year-earlier period including a capital gain of SEK 7.4 M from the divestment of the minority holding in Isogenica Ltd. A loss of SEK 118.6 M (loss: 99.3) was reported after tax.

### **Cash flow, liquidity and financial position**

Following the rights issue implemented during the period, cash and cash equivalents amounted to SEK 259.5 M at the end of the period, compared with SEK 138.7 M at the end of 2008.

Accordingly, cash flow for the period amounted to SEK 120.8 M (0.4), of which cash flow from operating activities was a negative SEK 123.3 M (neg: 87.6), cash flow from investing activities was SEK 0.0 M (neg: 66.8) and cash flow from financing activities was a positive SEK 244.1 M (154.9).

### **Comments on the Parent Company's earnings and financial position**

The operations of the Parent Company, Active Biotech AB, comprise Group-wide administrative functions. The Parent Company's net sales for the period amounted to SEK 1.8 M (3.4).

Operating expenses during the period totaled SEK 10.1 M (14.3) and net financial items amounted to income of SEK 0.4 M (9.4). Loss after financial items amounted to SEK 7.9 M (loss: 1.5). No investments in fixed assets were made during the period.

Cash and cash equivalents, including short-term investments, totaled SEK 244.0 M at the end of the period, compared with SEK 131.6 M on January 1, 2009.

### **Share capital**

Consolidated shareholders' equity at the end of the period amounted to SEK 294.4 M, compared with SEK 163.6 M at year-end 2008.

A total of 64,052,238 shares were outstanding at the end of the period. In the event of redemption of share warrants outstanding, the number of shares in Active Biotech would increase to a maximum of about 65.1 million.

At the end of the period, the equity/assets ratio for the Group was 48.7%, compared with 34.6% at year-end 2008. The corresponding figures for the Parent Company, Active Biotech AB, were 94.4% and 91.1%, respectively.

### **Organization**

The average number of employees was 90 (89), with the average number of employees in the research and development operation accounting for 73 (73). At the end of the period, the Group had 90 employees (89).

### **Implemented rights issue**

On May 7, 2009, the Annual General Meeting resolved to implement a guaranteed rights issue to strengthen the company's financial position and drive the development of the company's clinical project portfolio. The issue entitled existing shareholders with preferential rights to subscribe for one new share for each four shares held at an issue price of SEK 20 per share. The principal owners, MGA Holding AB (30.0%) and Nordstjernan AB (15.3%), had undertaken to subscribe for the full amount of shares corresponding to their preferential rights. In addition, MGA Holding AB and Nordstjernan AB had undertaken, in the event the issue was not fully subscribed, to subscribe for any additional shares not subscribed with the support of preferential rights.

The issue was oversubscribed by 71% and contributed approximately SEK 249 M to the company after issue expenses.

### **Outlook, including significant risks and uncertainties**

A vital factor for Active Biotech's financial strength and stability is the company's ability to develop pharmaceutical projects to the point at which partnership agreements can be entered into and the partner can assume responsibility for future development and commercialization of the project. During this development phase, the value of projects is expected to increase. The development of partnership agreements already signed and the addition of new agreements are assumed to have a significant impact on revenues and cash balances. The Board of Directors is of the opinion that the present level of available liquidity, the implemented rights issue and available financial alternatives will provide sufficient financial resources to finance the company's operations in line with current plans.

A research company such as Active Biotech is characterized by a high operational and financial risk, since the projects in which the company is involved are at the clinical phase, where a number of factors have an impact on the likelihood of commercial success. In brief, the operation is associated with risks related to such factors as pharmaceutical development, competition, advances in technology, patents, official requirements, capital requirements, currencies and interest rates. Since no significant changes took place with regard to risks and uncertainties during the period, refer to the detailed account of these factors presented in the directors' report in the 2008 Annual Report.

Condensed consolidated statement of comprehensive income SEK M	April - June		January - June		Full Year 2008
	2009	2008	2009	2008	
Net sales	3.0	2.6	5.2	5.8	53.5
Administrative expenses	-5.2	-6.5	-9.6	-12.2	-30.7
Research and development costs	-52.6	-48.6	-114.1	-98.4	-207.4
<b>Operating loss</b>	<b>-54.8</b>	<b>-52.5</b>	<b>-118.5</b>	<b>-104.7</b>	<b>-184.6</b>
Net financial items	-1.6	5.9	-0.1	5.4	4.0
<b>Loss after financial items</b>	<b>-56.4</b>	<b>-46.6</b>	<b>-118.6</b>	<b>-99.3</b>	<b>-180.6</b>
Tax	-	-	-	-	-1.0
<b>Net loss for the period</b>	<b>-56.4</b>	<b>-46.6</b>	<b>-118.6</b>	<b>-99.3</b>	<b>-181.6</b>
Comprehensive loss attributable to:					
Parent company shareholders	-56.4	-46.6	-118.6	-99.3	-181.6
Minority interest	-	-	-	-	-
<b>Net loss for the period</b>	<b>-56.4</b>	<b>-46.6</b>	<b>-118.6</b>	<b>-99.3</b>	<b>-181.6</b>
Other comprehensive income during the period					
Change in revaluation reserve	-	-	-	-	1.0
Change in translation reserve	-	-0.6	-	-0.6	-0.6
<b>Comprehensive loss for the period</b>	<b>-56.4</b>	<b>-47.2</b>	<b>-118.6</b>	<b>-99.9</b>	<b>-181.3</b>
Comprehensive loss attributable to:					
Parent company shareholders	-56.4	-47.2	-118.6	-99.9	-181.3
Minority interest	-	-	-	-	-
<b>Comprehensive loss for the period</b>	<b>-56.4</b>	<b>-47.2</b>	<b>-118.6</b>	<b>-99.9</b>	<b>-181.3</b>
Depreciation/amortization included in the amount of	2.4	2.3	4.7	6.8	11.5
Investments in tangible fixed assets	-	1.3	-	1.6	2.9
Earnings per share before dilution (SEK)	-1.02	-0.97	-2.22	-2.07	-3.66
Earnings per share after dilution (SEK)	-1.02	-0.97	-2.22	-2.07	-3.66
Weighted number of outstanding common shares before dilution (000s)	55 465	48 600	53 365	47 950	49 605
Weighted number of outstanding common shares after dilution (000s)	55 465	48 600	53 365	47 950	49 605
Number of shares at close of the period (000s)	64 052	51 242	64 052	51 242	51 242
Number of shares at close of the period, including warrants (000s)	65 052	52 572	65 052	52 572	52 572
<b>Consolidated balance sheet, condensed</b>					
SEK M	June 30				Dec. 31
	2009	2008	2009	2008	2008
Tangible fixed assets			323.1	325.9	324.6
Financial fixed assets			0.0	0.0	0.0
<b>Total fixed assets</b>			<b>323.1</b>	<b>325.9</b>	<b>324.6</b>
Current receivables			21.7	10.4	9.7
Short-term investments			-	75.0	-
Cash and cash equivalents			259.5	139.0	138.7
<b>Total current assets</b>			<b>281.2</b>	<b>224.4</b>	<b>148.4</b>
<b>Total assets</b>			<b>604.3</b>	<b>550.4</b>	<b>472.9</b>
Shareholders equity			294.4	244.8	163.6
Long-term liabilities			251.7	252.5	251.7
Current liabilities			58.2	53.1	57.6
<b>Total shareholders equity and liabilities</b>			<b>604.3</b>	<b>550.4</b>	<b>472.9</b>
<b>Consolidated statement of changes in shareholders equity</b>					
Opening balance			163.6	189.6	189.6
Personnel options program			-	1.5	1.5
New share issue			249.4	153.7	153.9
Net loss for the period			-118.6	-99.9	-181.3
<b>Balance at close of period</b>			<b>294.4</b>	<b>244.8</b>	<b>163.6</b>

Condensed consolidated cash-flow statement SEK M	January - June		Full Year 2008
	2009	2008	
Loss after financial items	-118.6	-99.3	-180.6
Adjustment for non-cash items, etc.	4.7	0.3	5.4
<b>Cash flow from operating activities before changes in working capital</b>	<b>-113.9</b>	<b>-99.0</b>	<b>-175.3</b>
Changes in working capital	-9.4	11.3	15.8
<b>Cash flow from operating activities</b>	<b>-123.3</b>	<b>-87.6</b>	<b>-159.5</b>
Investments in tangible fixed assets	-	-1.6	-2.9
Investments in financial fixed assets	-	-75.0	-
Decrease in financial fixed assets	-	9.8	9.8
<b>Cash flow from investing activities</b>	<b>-</b>	<b>-66.8</b>	<b>7.0</b>
New share issue	247.4	153.7	153.9
Loans raised/amortization of loan liabilities	-3.4	1.2	-1.2
<b>Cash flow from financing activities</b>	<b>244.1</b>	<b>154.9</b>	<b>152.6</b>
<b>Cash flow for the period</b>	<b>120.8</b>	<b>0.4</b>	<b>0.1</b>
<b>Opening cash and cash equivalents</b>	<b>138.7</b>	<b>138.6</b>	<b>138.6</b>
<b>Exchange-rate differences in cash and cash equivalents</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Closing cash and cash equivalents</b>	<b>259.5</b>	<b>139.0</b>	<b>138.7</b>
	<b>June 30</b>		<b>Dec. 31</b>
<b>Key figures</b>	<b>2009</b>	<b>2008</b>	<b>2008</b>
Shareholders equity, SEK M	294.4	244.8	163.6
Equity per share, SEK	4.60	4.78	3.19
Equity/assets ratio in the Parent Company	94.4%	73.9%	91.1%
Equity/assets ratio in the Group	48.7%	44.5%	34.6%
Average number of annual employess	90	89	89

Parent Company, income statement, condensed SEK M	April - June		January - June		Full Year 2008
	2009	2008	2009	2008	
Net sales	0.9	1.7	1.8	3.4	46.4
Administration expenses	-5.4	-7.5	-10.1	-14.3	-33.2
<b>Operating profit/loss</b>	<b>-4.6</b>	<b>-5.8</b>	<b>-8.3</b>	<b>-10.9</b>	<b>13.1</b>
<i>Profit/loss from financial items:</i>					
Profit/loss from participations in Group companies	-	-	-	-	37.6
Profit/loss from other securities and receivables classed as fixed assets	-	7.4	-	7.4	7.4
Interest income and similar income-statement items	0.1	0.9	0.4	2.0	5.5
Interest expense and similar income-statement items	-	-	0.0	-	0.0
<b>Profit/loss after financial items</b>	<b>-4.5</b>	<b>2.4</b>	<b>-7.9</b>	<b>-1.5</b>	<b>63.6</b>
Tax	-	-	-	-	-
<b>Net profit/loss for the period</b>	<b>-4.5</b>	<b>2.4</b>	<b>-7.9</b>	<b>-1.5</b>	<b>63.6</b>
	<b>June 30</b>				<b>Dec 31</b>
<b>Parent Company, balance sheet, condensed SEK M</b>	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>	<b>2008</b>
Tangible fixed assets	0.4	0.4	0.4	0.4	0.4
Financial fixed assets	202.5	229.4	202.5	229.4	202.5
<b>Total fixed assets</b>	<b>202.8</b>	<b>229.8</b>	<b>202.8</b>	<b>229.8</b>	<b>202.8</b>
Current receivables	14.5	68.8	14.5	68.8	10.3
Short-term investments	-	125.0	-	125.0	-
Cash and bank balances	244.0	64.6	244.0	64.6	131.6
<b>Total current assets</b>	<b>258.5</b>	<b>258.4</b>	<b>258.5</b>	<b>258.4</b>	<b>141.9</b>
<b>Total assets</b>	<b>461.3</b>	<b>488.1</b>	<b>461.3</b>	<b>488.1</b>	<b>344.7</b>
Shareholders equity	435.6	360.8	435.6	360.8	314.1
Long-term liabilities	-	-	-	-	-
Current liabilities	25.6	127.3	25.6	127.3	30.6
<b>Total equity and liabilities</b>	<b>461.3</b>	<b>488.1</b>	<b>461.3</b>	<b>488.1</b>	<b>344.7</b>

Any errors in additions are attributable to rounding of figures.

### **Accounting and valuation principles**

The interim report for the Group has been prepared in accordance with IAS 34, Interim Financial Reporting. In addition, relevant regulations from the Swedish Annual Accounts Act and the Securities Market Act have been applied. The same accounting policies and bases for calculations were applied in this interim report as in the most recent Annual Report.

Revised IAS 1 Presentation of Financial Statements is applied as of January 1, 2009. This amendment affected Active Biotech's accounting retroactively as of December 31, 2007. Among other consequences, this amendment results in revenues and costs that were previously recognized directly in equity now being recognized in a separate statement immediately after the income statement. Another change is that new designations for the financial statements have been used.

The Parent Company interim report has been prepared in accordance with the Swedish Annual Accounts Act and the Securities Market Act, which complies with the Swedish Financial Reporting Board's recommendation RFR 2.2, Accounting for Legal Entities. The same accounting policies and bases for calculations were applied in this interim report as in the most recent Annual Report.

### **Legal disclaimer**

This financial report includes statements that are forward-looking and actual results may differ materially from those anticipated. In addition to the factors discussed, other factors that can affect results are developments in research programs, including clinical trials, the impact of competing research programs, the effect of economic conditions, the effectiveness of the company's intellectual patent protection, obstacles due to technological development, exchange-rate and interest-rate fluctuations, and political risks.

### **Financial calendar**

Interim Report January-September 2009: November 5, 2009

Year-end Report 2009: February 11, 2010

The reports will be available from these dates at [www.activebiotech.com](http://www.activebiotech.com).

### **Board's assurance**

The Board of Directors and the President assure that the interim report provides an accurate overview of the Parent Company's and the Group's operations, position and earnings as well as describes significant risks and uncertainties facing the companies that are included in the Group.

Lund, August 6, 2009

Mats Arnhög  
*Chairman*

Klas Kärre  
*Board member*

Tomas Nicolin  
*Board member*

Magnhild Sandberg-Wollheim  
*Board member*

Peter Sjöstrand  
*Board member*

Peter Ström  
*Board member*

Camilla Davidsson  
*Employee rep/  
Board member*

Karin Hallbeck  
*Employee rep/  
Board member*

Tomas Leanderson  
*President and CEO*

***This interim report has not been audited by the company's auditors.***

**About Active Biotech**

*Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex™ for RA. Please visit [www.activebiotech.com](http://www.activebiotech.com) for more information.*

*Active Biotech is obligated to publish the information contained in this interim report in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on August 6, 2009 at 8:30 a.m.*

*Active Biotech AB*

*PO Box 724, SE-220 07 Lund*

*Sweden*

*Tel: +46 (0)46-19 20 00*

*Fax: +46 (0)46-19 11 00*